Myosteatosis, prognosis, and adverse events in breast cancer: a systematic review and meta-analysis of cohort studies
Name: NAIRA MARCELI FRAGA SILVA
Publication date: 11/08/2024
Examining board:
Name |
Role |
|---|---|
| ANDRESSA BOLSONI LOPES | Examinador Interno |
| DANIELA ALVES SILVA | Coorientador |
| THAIS MANFRINATO MIOLA | Examinador Externo |
| VALDETE REGINA GUANDALINI | Presidente |
Summary: Myosteatosis is associated with a variety of negative outcomes in oncology, but in patients with breast cancer (BC) the results have been conflicting. Therefore, we sought to critically analyze the evidence on the association between myosteatosis, overall survival, progression/disease-free survival and adverse treatment events in BC. The review was conducted and reported according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Two independent reviewers screened, selected, and assessed the records. Sixteen studies were included. Myosteatosis affected between 13 and 61% of the patients evaluated and the protocols for its analysis were heterogeneous and generally reported incompletely. The analysis of current data did not support the hypothesis of a relationship between myosteatosis in women with BC and overall survival (HR: 1.04; 95%CI 0.98-1.11; p=0.23; I²=64%) or disease/progression-free survival (HR: 1.15; 95%CI 0.91-1.45; p=0.24; I²=73%). In addition, the results on adverse events were not uniform, which prevented them from being analyzed together. Finally, these results highlight the urgent need to establish minimum parameters for the analysis of myosteatosis, as well as the need to develop new studies to confirm the absence of these associations or the possible influence of assessment methods on the results obtained.
